These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36943617)

  • 1. Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series.
    Fendian ÁM; Albanell-Fernández M; Tuset M; Pitart C; Castro P; Soy D; Bodro M; Soriano A; Del Río A; Martínez JA
    Infect Dis Ther; 2023 Apr; 12(4):1205-1216. PubMed ID: 36943617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
    Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
    Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives.
    Bavaro DF; Belati A; Diella L; Stufano M; Romanelli F; Scalone L; Stolfa S; Ronga L; Maurmo L; Dell'Aera M; Mosca A; Dalfino L; Grasso S; Saracino A
    Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
    Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
    J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant
    Campogiani L; Crea AMA; Minardi ML; Ansaldo L; Coppola L; Compagno M; Vitale P; Spalliera I; Malagnino V; Teti E; D'agostini C; Pennacchiotti C; Abate DN; Celeste MG; Andreoni M; Iannetta M; Sarmati L
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad627. PubMed ID: 38156051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review.
    Babidhan R; Lewis A; Atkins C; Jozefczyk NJ; Nemecek BD; Montepara CA; Gionfriddo MR; Zimmerman DE; Covvey JR; Guarascio AJ
    Pharmacotherapy; 2022 Jul; 42(7):549-566. PubMed ID: 35611627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant
    Meschiari M; Volpi S; Faltoni M; Dolci G; Orlando G; Franceschini E; Menozzi M; Sarti M; Del Fabro G; Fumarola B; Guarneri F; Lanza P; Lorenzotti S; Saccani B; Signorini L; Van Hauwermeiren E; Gatti M; Pea F; Castelli F; Mussini C
    JAC Antimicrob Resist; 2021 Dec; 3(4):dlab188. PubMed ID: 34909691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections.
    Gavaghan V; Miller JL; Dela-Pena J
    Infection; 2023 Apr; 51(2):475-482. PubMed ID: 36201152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
    Karruli A; Massa A; Andini R; Marrazzo T; Ruocco G; Zampino R; Durante-Mangoni E
    Int J Antimicrob Agents; 2023 Feb; 61(2):106723. PubMed ID: 36642233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
    Corcione S; De Benedetto I; Pinna SM; Vita D; Lupia T; Montrucchio G; Brazzi L; De Rosa FG
    J Infect Public Health; 2022 Sep; 15(9):975-979. PubMed ID: 35961239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
    Falcone M; Tiseo G; Leonildi A; Della Sala L; Vecchione A; Barnini S; Farcomeni A; Menichetti F
    Antimicrob Agents Chemother; 2022 May; 66(5):e0214221. PubMed ID: 35311522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem-Resistant
    Giannella M; Verardi S; Karas A; Abdel Hadi H; Dupont H; Soriano A; Santerre Henriksen A; Cooper A; Falcone M;
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad329. PubMed ID: 37496600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations.
    Marino A; Stracquadanio S; Campanella E; Munafò A; Gussio M; Ceccarelli M; Bernardini R; Nunnari G; Cacopardo B
    Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.